Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
AssigneeRhone-Poulenc Rorer International (Holdings) Inc.
InventorsJoseph Schlessinger, David Givol, Francoise Bellot, Richard Kris, George A. Ricca, Christopher Cheadle, Victoria J. South
Life of this patent
Estimating the term…
Abstract
Hybridoma cell lines producing monoclonal antibodies specific to the human epidermal growth factor receptor are disclosed. The antibodies are capable of inhibiting the growth of human tumor cells expressing human epidermal growth factor receptors. Therapeutic uses of these monoclonal antibodies by themselves and in combination with anti-neoplastic agents are also disclosed.
Claims9
A method for inhibiting the growth of human tumor cells that express human EGF receptors and are mitogenically stimulated by EGF, the method comprising administering an effective amount of an anti-neoplastic agent and an effective amount of a monoclonal antibody to a human cancer patient having said tumor cells;
- (i) wherein said antibody binds to the extra-cellular domain of the human EGF receptor of said tumor cell;
- (ii) wherein the antibody is not conjugated to the anti-neoplastic agent;
- and (iii) wherein the antibody inhibit the binding of EGF to the EGF receptor.
A therapeutic composition comprising an amount of monoclonal antibody and an anti-neoplastic agent effective to inhibit the growth of human tumor cells that express human EGF receptors and are mitogenically stimulated by human EGF in association with a pharmaceutical carrier;
- (i) wherein the antibody binds to the extracellular domain of the human EGF receptor of the tumor cells;
- (ii) wherein the antibody is not conjugated to the anti-neoplastic agent;
- and (iii) wherein the antibody inhibits the binding of EGF to the EGF receptor.
Dependencies are inferred from the claim text.